Treats anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small…. Sold as Ensacove. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Ensartinib Hydrochloride (sold as Ensacove), first approved Dec 18, 2024, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Ensacove | Part D | $0K | New | 0 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.Solid Advanced Tumor · Betta Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 | Recruiting | Mar 4, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA